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With a rapidly aging global human population, finding a cure for late onset neurodegenerative
diseases has become an urgent enterprise. However, these efforts are hindered by the lack of
understanding of what constitutes the phenotype of aged human microglia—the cell type that
has been strongly implicated by genetic studies in the pathogenesis of age-related neuro-
degenerative disease. Here, we establish the set of genes that is preferentially expressed by
microglia in the aged human brain. This HuMi_Aged gene set captures a unique phenotype,
which we confirm at the protein level. Furthermore, we find this gene set to be enriched in
susceptibility genes for Alzheimer’s disease and multiple sclerosis, to be increased with
advancing age, and to be reduced by the protective APOEε2 haplotype. APOEε4 has no effect.
These findings confirm the existence of an aging-related microglial phenotype in the aged
human brain and its involvement in the pathological processes associated with brain aging.
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Recent genetic studies of aging-related neurodegenerativediseases have uncovered many genetic variants that appearto function predominantly through the innate immune
system; these results suggest a fundamental role for myeloid cells,
including microglia (the resident innate immune cells of the
central nervous system) in the pathogenesis of diseases such as
Alzheimer’s disease (AD)1, Parkinson’s disease (PD)1 and
amyotrophic lateral sclerosis (ALS)2. However, the contribution
of microglia to the pathophysiology of these diseases is notor-
iously difficult to study in mouse, due to the differences in
age-related changes in microglial function between mice and
humans3, 4. The lack of a transcriptome-wide reference profile of
human microglia from aged individuals limits our understanding
of the aged microglia phenotype and function in humans,
particularly in advanced age. Understanding this temporal
dimension is critical given that aging is the largest risk factor for
late onset neurodegenerative diseases5.
In this study, we leverage two prospective cohort studies of
aging with brain autopsies6, 7, a novel protocol optimized for the
isolation of human microglial cells, and cDNA library construc-
tion for RNA sequencing (RNA-Seq) from small cell numbers to
perform a comprehensive assessment of the transcriptomic
landscape of aged human microglia and to create a resource for
the community of neurodegenerative disease investigators. We
establish the HuMi_Aged gene set that consists of genes primarily
expressed in microglia in the aged human brain. This gene set
displays many unique functional aspects that are highly relevant
to brain aging. Furthermore, we show that this gene set is
associated with neuropathological traits and susceptibility genes
of AD, confirming the involvement of this cell type in the
pathophysiology of the aging brain.
Results
Microglia isolation and library construction. We have
established an optimized pipeline for the isolation of microglia
from post mortem brain samples and an RNA-Seq library
construction approach that is specifically suited for use with low
cell numbers (described in detail in the Methods section).
Using mechanical tissue dissociation followed by magnetic
bead based enrichment and fluorescence activated cell sorting
(Supplementary Figure 1), this protocol yielded a microglia
population, that is free of CD45 high macrophages
(Supplementary Figure 2), infiltrating monocytes (Supplementary
Figure 2) or other blood cells (Supplementary Figure 3). The
resulting RNA-Seq dataset derives from the microglia of ten
donors; all microglia were extracted from a sample of dorsolateral
prefrontal cortex (DLPFC). All ten subjects had a non-zero
burden of amyloid and tau pathology (a characteristic of the aged
human brain; Supplementary Figure 4 and Supplementary
Table 1), and three of these subjects were diagnosed with AD
dementia (Supplementary Table 1).
Identification of the HuMi_Aged gene set. To define a set of
genes that are primarily expressed by microglia in the aged
human brain, we took advantage of existing DLPFC tissue-level
RNA-Seq data8 available from an independent set of participants
from the same cohorts (N = 540). By using a 4-fold increase in
microglia:bulk tissue expression as a threshold, we identified 1054
microglia-enriched genes (referred to as “the HuMi_Aged
gene set”; Fig. 1a and Supplementary Data 1). Among the
microglia-enriched genes we found known markers of microglia
(Fig. 1a); many of them in the top 100 expressed genes,
confirming the validity of our approach. However, not all
previously identified microglia genes were found to be microglia-
enriched in our dataset. Interestingly, many genes that were
microglia specific in the mouse (e.g., SALL19) were not part of the
aged human microglia core transcriptomic signature.
When we compared the HuMi_Aged gene set to other recently
published microglia core gene sets10, 11 we found that the
HuMi_Aged microglia signature had a unique set of genes, not
present in other adult10 or pediatric11 microglia signatures
(Supplementary Figure 5a). Among others, pathways associated
with DNA damage, telomere maintenance and phagocytosis were
significantly enriched in genes that were unique to the aged
human microglia signature (Supplementary Figure 5b).
Enrichment of HuMi_Aged in susceptibility genes. Using
series of hypergeometric tests we found that genes in the
HuMi_Aged gene set were enriched in susceptibility genes for AD
(p = 4.1 × 10−5) (Fig. 1b) and multiple sclerosis (p = 0.0032) but
not PD (p = 0.82), ALS (p = 0.7) or schizophrenia (p = 0.83)
(Supplementary Figure 6), as defined by the NHGRI-EBI catalog.
Nonetheless, a subset of PD (e.g., SLC50A1), ALS (ITPR2), and
schizophrenia (RENBP) susceptibility genes were part of the
microglia signature in the aged human brain. Interestingly,
RENBP was not found to be expressed in microglia from middle
aged brains12. Our findings therefore reinforce the earlier notion,
that within the brain, a significant amount of the genetic load that
influences the onset of certain neurodegenerative diseases may
exert its function through microglia. Focusing on late onset AD
(LOAD), we found that many well-known susceptibility genes
(CD33, INPP5D, MS4A4A, SORL1, and TREM2) are part of the
HuMi-Aged gene set, while others, such as SPI113, were not.
We also identified additional susceptibility genes not known
to function in microglia in the context of neurodegeneration
(e.g., SCIMP, SPPL2A14).
Relationship of the HuMi_Aged to traits and genotypes. We
took advantage of the large sample size of the bulk DLPFC
RNAseq dataset (N = 540) and examined how our HuMi_Aged
signature behaved in that tissue-level dataset with respect to traits
available in our cohort. For these analyses we created a
meta-feature for the HuMi_Aged gene set that resulted in a single
value for each participant (Supplementary Data 2). The associa-
tion of this meta feature was investigated using linear regression.
Interestingly, the expression level of the HuMi_Aged gene set in
the frontal cortex of the participants increased with advancing age
at death (p = 0.0012, Table 1), suggesting that the proportion of
microglia in the DLPFC may increase with age or that microglia
increase the expression of this transcriptional program over time.
However, the aged microglia signature is not associated with a
diagnosis of AD dementia or a global measure of AD pathology in
these tissue-level data; nonetheless, there is a suggestion that it
may relate to amyloid deposition (p = 0.011). These associations
do not change when we perform stratified analyses in subjects
with and without a clinical diagnosis of AD (Supplementary
Data 3). At the individual gene level, a small number of genes in
these ten participants were found to be associated with neuritic
plaques (NP), diffuse plaques, and neurofibrillary tangles (NFT)
after correction for multiple testing. These genes will require
further validation given the modest sample size (N = 10) of the
present study (Supplementary Figure 7).
From a genetic point of view, the APOE haplotype is associated
with the HuMi_Aged meta-feature (p = 0.0088), and, interest-
ingly, the effect appears to be driven not by APOE ε4 but by
APOE ε2, the haplotype that is protective for AD. In our
tissue-level data, APOE ε2 was associated with reduced expression
of HuMi_Aged (Fig. 1c) (p = 0.0064), consistent with the
predicted direction of effect.
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Identification of human microglia genes affected by aging. In
order to identify the microglia genes that are affected by aging in
the human cortex, we took advantage of another published adult
human microglia transcriptomic dataset, that is derived from
middle aged individuals12. We performed an exploratory study
comparing the transcriptomic profiles of middle aged (mean age
= 53, SD = ±5.29, N = 3) and our aged (mean age = 94.07, SD =
±0.95, N = 10) human microglia (Supplementary Figure 8a). By
assessing only those genes that were reliably detected in both
datasets (Supplementary Figure 8b; Materials and Methods), we
identified 1060 genes that were up-regulated (logFC> 2, adjusted
p-value> 0.05), and 1174 genes that were down-regulated in our
aged human microglia (Fig. 2a, Supplementary Data 4).
Importantly, both datasets were highly enriched in microglia
genes (Supplementary Figure 8c). Intriguingly, gene set enrich-
ment analysis (GSEA) of the differentially expressed genes iden-
tified the Amyloid fiber formation (Fig. 2b) REACTOME gene set
to be enriched for genes that are up-regulated in aged human
microglia, while the TGFβ signaling KEGG pathway (Fig. 2c) was
enriched for down-regulated genes. These results suggest that
human microglial aging may result both in gain of function as
well as in loss of function of certain transcriptional programs;
diminished TGFβ signaling highlights the perturbation of
homeostatic programs as microglia activate reactive pathways to
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Fig. 1 The HuMi_Aged and its relationship to genetic risk of AD. a Scatter plot depicting the distribution of gene expression values between the bulk DLPFC
(N= 540) and the isolated microglia (N= 10). Each dot represents a gene. The X and the Y axes show normalized expression values. One thousand fifty
four genes have been identified to be preferentially expressed by microglia (based on the differences in gene expression between the isolated microglia and
the bulk cortical tissue, FC> 4) in the aged human brain (dark blue dots). This set of genes has been coined the HuMi_Aged gene set. The HuMi_Aged
gene set contained many of the previously established microglia markers in the brain (black dots), such as CD74, CX3CR1, P2RY12, TREM2 or GPR34. b
Scatter plot showing the distribution of AD risk genes (black dots) in the transcriptomic universe defined by the bulk cortical and the microglial RNA-
Sequencing datasets. Each dot represents a gene. The X and the Y axes show normalized expression values. By using an overrepresentation test, the
HuMi_Aged gene set (blue dots) was found to be significantly enriched in Alzheimer’s disease risk genes (black dots; enrichment p-value= 4.1e-05). The
HuMi_Aged included AD risk genes, such as CD33, TREM2, INPP5D, APOC1 or SCIMP, while other AD risk genes (e.g., BIN1 or TREML2) were found to be not
specific to microglia in the aged brain. c APOE ε2 was associated with reduced expression of HuMi_Aged in the bulk tissue level data (N= 540). DLPFC
dorsolateral prefrontal cortex, FC fold change
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The proteome of aged human microglia. To assess whether
our transcriptomic approach faithfully captured genes that
were expressed at the protein level in microglia and could
therefore affect cellular function, we also generated a
proteomic profile from one sample of 5000 purified microglia
isolated with the same pipeline that was used to produce the
RNAseq dataset. Using LC-MS mass spectrometry, we
generated a shotgun proteomic profile consisting of 640 proteins
for which we have a measure of relative expression. As expected,
the detected proteins were distributed along the gene expression
spectrum, with a skew towards the more abundant gene
transcripts (Supplementary Figure 9a). By comparing the
expression levels of proteins and mRNA, we found that these
two measures were considerably correlated (rS = 0.3112,
p< 0.0001) (Supplementary Figure 9b). Twenty seven of the
detected proteins were also part of HuMi_Aged gene set. Gene
ontology analysis of the detected proteins revealed some of the
same REACTOME pathways that we found to be up-regulated in
the aged human microglia transcriptome, such as the
ER-Phagosome pathway (FDR = 3.19E-14) (Fig. 2d, e). The list
of proteins detected in aged human microglia is available in
Supplementary Data 5.
Discussion
Here, we present a novel microglia isolation protocol and RNA-
Seq library construction approach to create transcriptomic pro-
files from autopsy-derived microglia using only 5000 cells per
individual. This number has been previously empirically estab-
lished in our laboratory to be the lowest cell number at which the
stochastic drift in population mean is no longer substantial. Given
that current transcriptomic approaches require hundreds of
thousands of microglia cells10, 11 and the availability of fresh
autopsy samples from well-characterized subjects is very limited,
the protocol presented here will be a useful tool for the scientific
community in order to most efficiently utilize the available pre-
cious human brain specimens, especially in the case of samples
where viability is compromised, such as those affected by chronic
neurodegeneration and/or aging. Furthermore, we provide the
scientific community with the first transcriptomic atlas of aged
human microglia (publicly available at http://shiny.maths.usyd.
edu.au/Ellis/MicrogliaPlots website). This RNA-Sequencing
dataset is derived from quasi-centenarian donors of the ROS
and MAP cohorts.
It was beyond the scope of this study to discriminate between
microglia-derived macrophages and infiltrating monocyte-
derived macrophages, primarily due to the current lack of
markers that would reliably allow us to make that distinction in
human samples. Nonetheless, the lack of a CD45high sub-
population in our preparations further supports that our micro-
glia preparations are largely devoid of blood-borne monocytes
and perivascular macrophages, both of which would have shown
up on the scatter plots as a small CD11b+/CD45high sub-
population on top of the CD11b+/CD45+ microglia population.
Furthermore, the high expression of the microglia specific genes
(many of whose expression was close to the 100th percentile)
confirms that blood borne monocyte contamination was negli-
gible; the lack of considerable CCR2 expression in our dataset
shows that our preparations were also free from recently recruited
tissue infiltrating inflammatory monocytes.
By combining our microglia transcriptomic profiles with
existing cortical RNAseq data from an independent set of subjects
from the same cohort, we derived the HuMi_Aged gene set and
have illustrated the utility of this resource by showing that it
captures an important fraction of genetic susceptibility to both
AD and MS. In particular, we report the intriguing result that the
APOEε2 haplotype is associated with a reduced HuMi_Aged
signature, consistent with its role as a protective factor in AD, and
this observation aligns with recent reports that APOE may
interact with microglial genes such as TREM215–17. APOEε4 is a
much stronger risk factor for AD but does not appear to be
related to this microglial signature and most likely exerts its effect
through another mechanism.
Importantly, we also found that the HuMi_Aged core microglia
profile displayed a number of differences in relation to the already
available pediatric and adult microglia signatures. Functional
annotation of the genes that were unique to the aged human
microglia signature presented here revealed that cellular and
organismal aging related pathways and biological processes were
primarily affected. These findings confirm the notion, that the
aged human brain harbors a distinctive microglia phenotype,
whose identity is shaped by cell autonomous/intrinsic (DNA
damage response, telomere maintenance) as well as extrinsic
(decline in homeostatic and increase in phagocytic signaling from
the brain parenchyma) factors that are unique to the aging brain
environment.
Thus, the HuMi_Aged gene set can be used to more accurately
explore the role of microglia in other tissue-level datasets from
older brains. Increasing our sample size will allow us to more
directly dissect the contribution of microglia to brain aging and
neurodegenerative diseases as current tissue level profiles prob-
ably under-estimate the contribution of microglia which makes
up a small proportion of the tissue and often have relatively small
amounts of RNA. Nonetheless, this resource will be a critical
reference for efforts to optimize in vitro systems (using either
monocytes18 or induced pluripotent stem cell-derived microglial
like cells19–21) for neurodegenerative disease studies. Finally, our
initial proteomic profile not only validates our transcriptomic
data but also presents a number of proteins that could be targets
for developing novel markers of human microglia in histological
studies and for the development of new PET ligands with which
to assess the immunologic state of the aged human brain.
Methods
Cohorts and donors. The biological specimens used in this study originated from
two prospective studies of aging: the Religious Orders Study (ROS)6 and the
Memory and Aging Project (MAP)7. Participants have to be at least 53 (ROS) or 55
(MAP) years old and non-demented at enrollment and sign an Anatomical Gift
Act agreeing to donate their brain and spinal cord at the time of death. Thus, they
represent a sample of the older population from the Chicago, IL metropolitan area.
Each subject undergoes annual neuropsychologic evaluations while alive and a
Table 1 The clinicopathological trait associations of
HuMi_Aged
Trait Estimate Std. error t-value p-value
Age at death 0.0046 0.0014 3.2633 0.0012
Sex −0.0399 0.0194 −2.0560 0.0403
Clinical AD 0.0282 0.0193 1.4623 0.1443
Global AD
pathology
0.0174 0.0267 0.6500 0.5160
Amyloid load 0.0219 0.0086 2.5575 0.0108
Tau tangle
density
0.0021 0.0075 0.2732 0.7848
APOE
haplotype
0.0061 0.0023 2.6285 0.0088
APOEe4 count 0.0306 0.0199 1.5412 0.1239
APOEe2 count −0.0625 0.0228 −2.7387 0.0064
A meta-feature constructed from the HuMi_Aged gene set revealed its association with age at
death and APOE ε2 in the bulk tissue RNA-Seq dataset (N= 540). Please note, the reference sex
was male—women have a greater HuMi_Aged signature, on average. Five hypotheses were
tested in primary analysis, accordingly the significance threshold was p < 0.01
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structured, quantitative neuropathologic examination at autopsy. All brain
autopsies, experiments, and data analysis were done in compliance with protocols
approved by the Partners Human Research Committee and the Rush University
Institutional Review Board. The data presented in this study originates from ten
donors. The clinicopathological characteristics of the participants are shown in
Supplementary Table 1. Their mean age at death was 95 years and 80% of them
were female. Nine out of ten of the participants showed a range of amyloid and tau
pathology accumulation that is typical in this type of older, population-based
sample. Three of the donors were ante mortem diagnosed with clinical AD.
Brain autopsy and shipping of brain specimens. To obtain the midfrontal gyrus
(BA 9/46) a 1.5 cm × 1.5 cm thick section is cut off from the first cerebral slab
anterior to the caudate. After weighing, the tissue is placed in ice-cold transpor-
tation medium (Hibernate-A medium (Gibco, A1247501) containing 1% B27
serum-free supplement (Gibco, 17504044) and 1% GlutaMax (Gibco, 35050061))
and shipped overnight at 4 °C with priority shipping. Brain specimens were dis-
tributed for this project from autopsies taking place Sunday morning to Thursday.
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Fig. 2 The phenotype of aged human microglia. Functional annotation reveals that human microglia aging manifests itself as loss of function as well
as gain of function changes in phenotype. a Volcano plot depicting the results of differential gene expression analysis between the Zhang et al. (middle
aged microglia; N= 3) and our dataset (aged microglia; N= 10). One thousand sixty genes were found to be upregulated while 1174 genes were
downregulated with aging. b, c GSEA enrichment plots of representative gene sets that were significantly enriched in either downregulated (b) or
upregulated (c) genes. The TGFβ signaling pathway gene set was enriched in downregulated genes (loss of function with aging, (b)) while the Amyloid
fiber formation pathway was enriched in upregulated genes (gain of function with aging, (c)). d Pathway analysis of the genes that were significantly
upregulated with aging in microglia in the two RNA-Seq datasets. e Pathway analysis of the proteins detected with a shotgun proteomic approach in aged
human microglia. Please note the significant overlap between the functional phenotypes revealed by the two approaches (overlapping REACTOME entities
highlighted in orange). Legends in d and e: orange diamonds (–log2(FDR)), columns (Percentage of entities). GSEA gene set enrichment analysis, FDR false
discovery rate
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Microglia isolation and sorting. Upon arrival of the autopsy brain sample, the
cerebral cortex and the underlying white matter were dissected under a stereo-
microscope. All procedures were performed on ice. Only microglia isolated from
the grey matter were used in this study. The dissected tissue was placed in HBSS
(Lonza, 10-508F) and weighed. Subsequently the tissue was homogenized in a 15
ml glass tissue grinder—0.5 g at a time. The resulting homogenate was filtered
through a 70 μm filter and spun down with 300 g for 10 min. The pellet was
resuspended in 2 ml staining buffer (PBS (Lonza, 17-516F) containing 1% FBS) per
0.5 g of initial tissue and incubated with anti-myelin magnetic beads (Miltenyi,
130-096-733) for 15 min according to the manufacturers specification. The
homogenate was than washed once with staining buffer and the myelin was
depleted using Miltenyi large separation columns. The cell suspension was spun
down and incubated with anti-CD11b magnetic beads (Miltenyi, 130-049-601,
clone M1/70) for 15 min. Following a wash with staining buffer the CD11b+ cells
were isolated on a Miltenyi MS column while the CD11b− fraction was cryopre-
served using FBS containing 10% DMSO. The CD11b positive fraction was than
incubated with anti-CD11b AlexaFluor488 (BioLegend, 301318, clone ICRF44) and
anti-CD45 AlexaFluor647 (BioLegend, 304018, clone HI30) antibodies as well as
7AAD (BD Pharmingen, 559925) for 20 min on ice. Subsequently the cell sus-
pension is washed twice with staining buffer, filtered through a 70 μm filter and the
CD11b+/CD45+/7AAD− cells (Supplementary Figure 2b) were sorted on a BD
FACS Aria II sorter. Cells were sorted in A1 well of a 96 well PCR plate
(Eppendorf, 951020401) containing 25 μl of TCL buffer (Qiagen, 1031576) with 1%
beta mercaptoethanol (Sigma, M3148). Following FACS the lysate was vigorously
vortexed for 30 s, spun down, snap frozen on dry ice and stored at −80 °C until
further processing.
Library construction and sequencing. Library construction was performed using
the SmartSeq-2 protocol described in detail elsewhere22 with minor modifications.
Briefly, the 96 well plates (Eppendorf, 951020401) were thawed on ice and spun
down. RNA Isolation. 2.2 × volume of RNA-SPRI (Beckman Coulter, A63987)
beads were added to the cell lysate, mixed, incubated for 10 min at room tem-
perature and placed on a magnet (Thermo Fischer, 12027) for 5 min. The super-
natant was removed and the beads were washed with 80% ethanol (VWR, 89125-
170) three times, let to dry on air for 10 min on the magnet and subsequently
resuspended in Master Mix 1 (containing RT primers 10 μM (IDT—Custom,
sequence below), dNTP mix 10 mM (Thermo-Fischer, R0192) and RNase-inhibitor
4 U/μl (Clontech, 2313B) in water). The plate is then incubated at 72 °C for 3 min
in a thermocycler and then placed on ice. Whole Transcriptome Amplification.
Subsequently the beads are dispersed in Master Mix 2 (containing Maxima Buffer
(Thermo-Fischer, EP0753), betaine 5M (Sigma-Aldrich, B0300-1VL), MgCl2 10
mM (Sigma-Aldrich, M1028), TSO 10 μM (Exiqon Custom, sequence below),
RNase inhibitor 40 U/μl, Maxima RNaseH-minus RT 200 U/μl in water) and a PCR
run is performed on the thermocycle with the following parameters: Hold (42 °C,
90 min), 10 cycles (50 °C, 2 min; 42 °C, 2 min), Hold (70 °C, 15 min). PCR Pre-
amplification. The plate is then removed from the thermocycle, Master Mix 3
(containing ISPCR primer 10 μM (IDT custom, sequence below) KAPA HiFi
HotStart ReadyMix (KAPA BioSystems, KK2602) in water) is added, and run again
with the following parameters: Hold (98 °C, 3 min), 14 cycles (98 °C, 15 s; 67 °C, 20
s; 72 °C, 6 min), Hold (72 °C, 5 min). DNA Cleanup. The PCR products were
purified with 0.8 × AMPure XP SPRI beads (Beckman Coulter, A63880). The
AMPure XP SPRI beads were added to the sample, mixed thoroughly, incubated at
room temperature for 6 min and placed on the magnet for 6 min. The supernatant
was pipetted off and the beads were washed with 70% ethanol 2 times and than let
to dry on room temperature for 10 min. The material was eluted from the beads in
TE (TEKNOVA, T0228), removed the beads from the eluent with a magnet and the
eluent was than transferred to a new 96 well PCR plate for a second round of PCR
product purification with AMPure XP SPRI beads. Quality control. The quality and
the quantity of the cDNA were assessed with Qubit DNA HS (Life Technologies,
Q32854) and BioAnalyzer DNA HS assays (Agilent, 5067-4626). Library con-
struction. All samples were diluted to the concentration range of 0.1–0.2 ng/μl in
order to be used with the Nextera XT kit (Illumina, FC-131-1096) for library
construction. In a fresh plate TD, ATM and the input sample were mixed and than
placed in a thermocycler for the following program: Hold (55 °C, 10 min), Hold
(10 °C, ∞); following which it is placed on ice. Subsequently NT, NPM, and mixed
indices were added to the samples and the plate was run using the following
parameters: Hold (72 °C, 3 min), Hold (95 °C, 30 s), 12 cycles: (95 °C, 10 s; 55 °C,
30 s; 72 °C, 60 s), Hold (72 °C, 5 min), Hold (4 °C, ∞). Sample cleanup. Subsequently
the samples were pooled and DNA cleanup was performed by adding 0.9 × volume
of AMPure XP SPRI beads, incubating for 5 min on room temperature, placing the
sample on a magnet for 5 min, washing the beads twice with 80% ethanol and then
eluting the cDNA with TE. The cleanup step is repeated once. Quality control. The
quality and the quantity of the cDNA were assessed with Qubit DNA HS and
BioAnalyzer DNA HS assays. Sequencing. The pool of ten samples was sequenced






Quality control and data processing of RNA-Seq data. RNA-Seq reads in
FASTQ format were inspected using FASTQC program. Barcode and adapter
contamination, low quality regions (10 bp at beginning of each fastq reads) were
trimmed using FASTX-toolkit. We then used Tophat (2.1.0) to align trimmed reads
to human reference genome sequences (hg19) and transcript annotation from
Gencode (v19) then applied Cufflinks (2.2.1) to estimate gene and isoform abun-
dance. The estimation of abundance is in FPKM format. We then performed the
following normalization approach: first, we filtered out low expressed genes with
FPKM < 0.1 in more than two samples, resulting in expression levels for 9489
genes. Then we used voom method in limma23 package to normalize filtered FPKM
values.
Identification of microglia enriched genes. Given that microglia constitute only
12% of the cells in the prefrontal cortex and are known to have very low RNA
content, our argument was that genes that will be significantly highly expressed in
the isolated microglia samples, when compared to the bulk, will be most likely
primarily expressed by microglia. To make the microglia and bulk samples more
comparable the mapped genes were first filtered to only include those with a
uniprot identifier. Further normalization was then performed, by comparing the
log gene expression of a sample to the average of all samples, a robust linear model
was used to normalize out any residual GC content and gene length artifacts. Then,
by contrasting the bulk RNA-Seq data with the gene expression profiles of isolated
microglia and using a fold change cut off of 4, we identified 1054 genes that were
enriched in microglia (Fig. 1a; FC genes in Supplementary Data 1). Seven hundred
seventy one genes reached statistical significance (PVAL genes; Supplementary
Data 1). Statistical significance depends on the variability between samples, and in
our case, this might originate from the microglial responses to pathological features
present in the brains of the donors, that had varying amounts of amyloid load and
tau pathology (Supplementary Table 1). In order not to exclude the genes that are
responsive to the aging brain environment, we decided to use the FC genes for
downstream analysis.
Over-representation analysis. The enrichment of the HuMi_Aged gene
set in genes associated with neurodegenerative disease and psychiatric disorders
was tested with an over-representation analysis. Genes that had previously
been associated with neurodegenerative disease and psychiatric disorders were
sourced from the NHGRI-EBI Catalog of published genome-wide association
studies24.
Association with traits. A meta-feature was created to capture the change in
expression of the HuMi_Aged gene set as a collective in the bulk tissue and assess
its association with various AD an aging associated traits. To do this each gene was
standardized to have variance equal to 1 and then the expression of all genes in the
HuMi_Aged gene set was averaged over each sample. A series of t-tests were then
used to test for association of the meta-feature with various clinical, pathological
and mutation variables.
Differential gene expression. We contrasted the gene expression levels of
aged human microglia with a previously published microglia transcriptomic
dataset derived from middle-aged individuals (NCBI GEO accession number:
GSE73721)12. The differential gene expression analysis was performed using
limma package23. We identified 2234 genes (logFC > 2 and logFC<−2, adjusted
p-value< 0.05, Supplementary Data 4) that were differentially expressed in aged
human microglia.
GSEA and pathway analysis. GSEA was performed by pre-ranked GSEA module
in GenePattern25. Pathway analysis was performed using the publically available
platform REACTOME with default setting (www.reactome.org).
Proteomic analysis. For proteomic analysis microglia were isolated as described
above. 5000 CD11b+/CD45+/7AAD- cells were sorted in A1 well of a 96 well plate
containing 100 μl of PBS. Following FACS the cells were spun down after which all
but 10 μl of PBS was removed from A1 well and the plate was than snap frozen on
dry ice and stored at −80 °C until further processing. Sorted cell pellets were lysed
and extracted by adding 10 μL of homogenization buffer (8 M urea, 10 mM
dithiothreitol, 50 mM Tris pH = 8) followed by 30 s in a bath sonicator. The lysate
was then incubated at 37 °C for 30 min to denature and reduce the proteins.
Protein solution was quantitatively transferred to a low retention LC vial
(Waters) using 20 μL of 50 mM Tris pH = 8. SNaPP analysis was carried out as
described previously26, 27. Briefly, 25 μL of sample was injected onto a 150 µm× 2
cm immobilized enzyme reactor for digestion. Following digestion, peptides
were separated using a 180 min gradient on an in-house 50 µm× 75 cm C18
(Phenomenex) analytical column. The SNaPP system was coupled to an
Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific) operated in top
speed mode. Fragmentation was carried out in the ion trap with maximum
injection time of 250 ms for MS2 to increase sensitivity for low intensity ions.
The label-free data was quantified using the iBAQ (intensity based absolute
quantification) approach28.
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Immunohistochemistry. Immunohistochemistry was performed as described
elsewhere29. Briefly brains were removed and processed according to a standard
protocol. One hemisphere was cut coronally into 1 cm slabs and fixed in 4%
paraformaldehyde. β-amyloid deposits and PHFtau tangles were assessed in 20 µm
sections. Immunohistochemistry and computer-assisted image analysis were used
for β-amyloid (clone 4G8, 1:9000 Covance Labs, Madison, WI) and stereology was
used for PHFtau tangles (clone AT8, 1:2000; ThermoScientific, Waltham, MA)
across eight different brain regions including the entorhinal cortex, the hippo-
campus at CA1, superior frontal cortex (Broadmann area [BA] 6/8), mid frontal
cortex (BA 46/9), inferior temporal cortex (BA 20), angular gyrus cortex (BA 39/
40), cingulate gyrus (BA 32/33) and calcarine cortex (BA 17). β-amyloid load and
the density of PHFtau tangle density was obtained by averaging the mean per-
centage area per region, across all regions. The absence of β-amyloid was char-
acterized by a β-amyloid load of zero in all the eight immunostained sections. NP
and NFT were identified with modified Bielshowsky stain in 6 µm sections in five
different regions (entorhinal cortex, hippocampus at CA1, midfrontal cortex,
middle temporal gyrus, and inferior parietal cortex). CERAD criteria assessed NP
burden and a Braak staging assessed the distribution and severity of NFT
pathology. The diagnosis of pathologic AD was based on the National Institute on
Aging (NIA)–Reagan criteria (1997).
Technical considerations. Since the brain tissue is obtained at autopsy with a
postmortem delay of, on average, 7 h, the release of surviving monocytes from the
clotted blood present in the blood vessels of the brain, with the non-enzymatic
approach used in this study, is exceedingly unlikely. The high expression of the
markers previously reported to be microglia specific when compared to monocytes
(e.g., P2RY12, TMEM119, TREM2, GPR34, CX3CR1)30–32 in our preparations
(Fig. 1a and Supplementary Figure 8c) further supports this scenario. The lack of
CD11b−/CD45+ cells on the flow cytometry scatter plots (Supplementary Fig-
ure 2b) further supports the idea, that there was no blood borne immune cell
contamination in our preparations. Nonetheless, it was beyond the scope of this
study to discriminate between microglia derived macrophages and infiltrating
monocyte derived macrophages, primarily due to the current lack of technologies
that would reliably allow us to make that distinction in human samples. Despite the
differences in the mode of isolation (CD11b/CD45 based FACS versus CD45 based
immunopanning), there was an almost perfect overlap between the Zhang and our
dataset in terms of the expression levels of previously established microglia
marker genes, since in both datasets they scored close to the 100th percentile
(Supplementary Figure 8c). This increases our confidence that the observed
differences in gene expression are, with some contribution from potential regional
and disease specific differences, primarily due to organismal aging and/or cellular
senescence.
Data availability. The RNA-Sequencing data originating from the bulk
dorsolateral prefrontal cortex (DLPFC; 540 donors) and from purified
microglia (10 donors) from the same brain region is available at Synapse
(https://www.synapse.org/#!Synapse:syn3219045 and syn11468526). The microglia
RNA-Sequencing dataset is also available and searchable at http://shiny.maths.
usyd.edu.au/Ellis/MicrogliaPlots/. Please note, that the searchable platform will
ultimately move to the website of the Center for Translational and Computational
Neuroimmunology (at Columbia University Medical Center, New York), which is
currently under development. For all other inquires please contact the corre-
sponding authors.
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